MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the ...

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...

In some good news for the US vaccines developer, whose stock has fallen 66% in the past 12 months, Moderna on Friday ...

Georgia has suspended all poultry activities after bird flu was confirmed during a commercial poultry operation. The positive ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Georgia officials halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...